UK Markets open in 7 hrs 58 mins

Global Immuno-Oncology Diagnostics Market Forecasts 2021-2025: Revolution in Cancer Therapy to be Driven by New Diagnostics

Research and Markets
·6-min read

Dublin, Nov. 11, 2020 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Diagnostics Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates. Including Executive/Consultant Guides and Customized Forecasting/Analysis. 2021 to 2025" report has been added to ResearchAndMarkets.com's offering.

Revolution in cancer therapy to be driven by new diagnostics: Histology, genomics and liquid biopsy converge - COVID-19 changes the focus of research.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity and the surprising impact of COVID-19 on what might seem to be an unrelated area.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.

The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

Key Topics Covered:

Market Guides

  • Situation Analysis & Impact of COVID-19 Pandemic

  • Guide for Executives and Marketing Staff

  • Guide for Investment Analysts and Management Consultants

1. Introduction and Market Definition
1.1 What are Immuno-Oncology Diagnostics?
1.2 Immuno-oncology - the looming cure
1.2.1 Immuno-oncology Diagnostics Takes a Leading Role
1.3 Market Definition
1.4 Methodology
1.5 U.S. Medical Market and laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Immunotherapy - Guide to Immune Technologies
2.0 The Immune System
2.0.1 Innate immune system
2.0.1.1 Surface barriers
2.0.1.2 Inflammation
2.0.1.3 Complement system
2.0.1.4 Cellular barriers
2.0.1.5 Natural killer cells
2.0.2 Adaptive immune system
2.0.2.1 Lymphocytes
2.0.2.2 Killer T cells
2.0.2.3 Helper T cells
2.0.2.4 Gamma delta T cells
2.0.2.5 B lymphocytes and antibodies
2.0.3 Tumor immunology - the immune surveillance system
2.1 Immuno Oncology Diagnostics
2.1.1 Checkpoint Assays
2.1.2 Cytokine Assays
2.1.3 Genomic Germline
2.1.4 Genomic Tumour
2.1.5 Tumor Microenviroment
2.1.6 Others

3. Industry Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Genomic Instrumentation Supplier
3.1.3.1 Cell Separation and Viewing Instrumentation Supplier
3.1.4 Pharmaceutical/Reagent Supplier
3.1.5 Independent Testing Lab
3.1.6 Public National/regional lab
3.1.7 Hospital lab
3.1.8 Physician Lab
3.1.9 Audit Body
3.1.10 Certification Body

4. Market Trends
4.1 Factors Driving Growth
4.1.1 Outcome potential
4.1.2 Companion Diagnostics
4.1.3 Funding
4.1.4 Technology Environment
4.1.5 Target Solutions
4.2 Factors Limiting Growth
4.2.1 Complex Role of Diagnostics
4.2.2 Clinical Trials Role
4.2.3 Protocols
4.3 Diagnostic Technology Development
4.3.1 Combinations - Issues and Complexity
4.3.2 Shifting Role of Diagnostics
4.3.3 Multiplexing and Foundation One
4.3.4 The Disruption Dynamic
4.3.5 The Race for Biomarkers
4.3.6 The Next Five Years

5. Cancer Immuno-Oncology Diagnostics Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section

  • Qiagen Expands Immuno-Oncology Portfolio

  • Immune Profiling System Redirected to Fight COVID-19

  • IncellDx Awarded PD-L1 Detection Patent

  • FDA Approves CDx for Trastuzumab

  • Promega Nabs CE Mark for Microsatellite Instability IVD

  • ArcherDx partners with AstraZeneca for Immuno-Oncology

  • Germline Results Guides Precision Therapy

  • Agilent PD-L1 Assay Gets FDA Approval

  • Bayer, OrigiMed Form Companion Diagnostic Development Alliance

  • Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy

  • SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological

  • Signatures

  • Biocare Medical Launches 7 Novel IVD Antibodies

  • Oncocyte to Acquire Insight Genetics for $12M

  • Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm

  • Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment

  • Generex to Merge with NuGenerex Immuno-Oncology

  • Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop

  • Companion Diagnostics for Cancer Therapies

  • Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative

  • Breast Cancer

  • Icon Acquires MolecularMD

  • Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca

  • Tumor Mutational Burden as Predictor of Immunotherapy Success

6. Profiles of Key Immunotherapy Companies

  • Genomics

  • Abbott Laboratories

  • Abcam

  • Adaptive Biotechnologies

  • Aethlon Medical

  • Agena Bioscience

  • Angle plc

  • Apocell

  • ARUP Laboratories

  • Beckman Coulter

  • Becton Dickinson

  • Bioarray Genetics

  • BioCartis

  • Biocept

  • Biodesix Inc

  • BioFluidica

  • BioGenex 38 bioMerieux

  • Bio-Rad

  • Bio-Techne

  • Bristol-Myers Squibb

  • Cancer Genetics

  • Caris Molecular Diagnostics

  • CellMax Life

  • Charles River Laboratories

  • Chronix Biomedical

  • Circulogene

  • Clearbridge BioMedics

  • Clinical Genomics

  • Cynvenio

  • Cytolumina Technologies Corp

  • CytoTrack

  • Dako (Agilent)

  • Diagnologix LLC

  • Epic Sciences

  • Exosome Diagnostics

  • Fluidigm Corp

  • Fluxion Biosciences

  • Foundation Medicine

  • Freenome

  • Genomic Health

  • GenomOncology

  • GRAIL

  • Guardant Health

  • HalioDx

  • Horizon Discovery

  • HTG Molecular Diagnostics

  • iCellate

  • Illumina

  • Incell Dx

  • Inivata

  • Integrated Diagnostics

  • Invivoscribe

  • Leica Biosystems

  • Luminex

  • MDx Health

  • Merck & Co., Inc

  • MIODx

  • Molecular MD

  • MRM Proteomics Inc

  • Myriad Genetics/Myriad RBM

  • Nanostring

  • Natera

  • Neogenomics

  • New Oncology

  • Oncocyte

  • Ortho Clinical Diagnostics

  • Perkin Elmer

  • Personal Genome Diagnostics

  • Pfizer

  • Promega

  • Protagen Diagnostics

  • Qiagen

  • Quanterix

  • Rarecells SAS

  • Roche Diagnostics

  • Siemens

  • Silicon Biosystems

  • SkylineDx

  • SRI International

  • Sysmex

  • Thermo Fisher

  • Trovagene

  • Vortex Biosciences

7. The Global Market for Immuno-Oncology Diagnostics
7.1 Global Market Overview by Country
7.1.1 Global Market by Country
7.1.2 Global Market by Country
7.2 Global Market by Assay Type - Overview
7.2.1 Global Market by Assay Type
7.2.2 Global Market by Assay Type - Base/Final Year Comparison
7.2.3 Global Market by Assay Type - Base Year
7.2.4 Global Market by Assay Type - End Year
7.2.5 Global Market by Assay Type - Share by Year
7.2.6 Global Market by Assay Type - Segments Growth

8. Global Immuno-Oncology Diagnostic Markets - By Assay Type
8.1 Checkpoint
8.2 Cytokine
8.3 Germline Genetic
8.4 Genetic Tumor
8.5 Tumor Microenvironment
8.6 Other

9. Appendices
9.1 FDA Cancer Drug Approvals by Year
9.2 Clinical Trials Started 2010 to 2016
9.3 Prevalence of Cancer Treatments

For more information about this report visit https://www.researchandmarkets.com/r/xyvqj9

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900